-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17

Benzinga·05/27/2026 17:32:11
Listen to the news
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.